Biology of Cox-2: An application in cancer therapeutics

Current Drug Targets

Volumn 12, Issue 7, 2011, Pages 1082-1093

  Khan, Zakir ^a,e   Khan, Noor ^b   Tiwari, Ram P ^c   Sah, Nand K ^d   Prasad, G B K S ^e   Bisen, Prakash S ^e  

^a INSERM U955   (France)

^b CSIR NATIONAL BOTANICAL RESEARCH INSTITUTE   (India)

^c RFCL Limited   (India)

^d T M BHAGALPUR UNIVERSITY   (India)

^e JIWAJI UNIVERSITY   (India)

Author keywords

Angiogenesis; Apoptosis; Cancer; Celecoxib; Chemotherapy; Cyclooxygenase 2 (Cox 2); Prostaglandin; Radiotherapy

Indexed keywords

ARACHIDONIC ACID; AROMATASE; CAPECITABINE; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; FLUOROURACIL; GEFITINIB; ICOSANOID; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN; TRASTUZUMAB;

ACTINIC KERATOSIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASAL CELL NEVUS SYNDROME; BLADDER CANCER; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; ESOPHAGUS CANCER; ESTROGEN SYNTHESIS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; IMMUNOSURVEILLANCE; INTESTINE POLYP; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; RNA SPLICING; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR PROMOTION; UPREGULATION; UTERINE CERVIX CANCER;

EID: 79958088295     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011795677764     Document Type: Article

References (143)

1. Kawahito SH, Wilder Y, Hasiramoto RL, et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995; 55: 3785-9.
2. Sellers RS, Radi ZA, Khan NK. Pathophysiology of cyclooxygenases in cardiovascular homeostasis. Vet Pathol 2010; 47: 601-13.
3. Smith WL, Garavito RM, Dewitt DL. Prostaglandin endoperoxide H synthases (cyclooxigenases)-1 and-2. J Biol Chem 1996; 271: 33157-60.
4. Wu KK. Cyclooxigenase-2 induction: molecular mechanism and pathophysiologic roles. J Lab Clin Med 1996; 128: 242-5.
5. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010; DOI: 10.1155/2010/215158.
6. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24: 96-102.
7. Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 2004; 64: 7210-15.
8. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
9. de Heer P, Gosens MJ, de Bruin EC, et al. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res 2007; 13: 2955-60.
10. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86: 667-71.
11. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007; 97: 1523-31.
12. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
13. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232-240.
14. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC. Role of prostaglandin E-2-dependent angiogenic switch in cyclooxygenase-2-induced breast cancer progression. Proc Natl Acad Sci 2004; 101: 591-6.
15. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003; 17: 1640-7.
16. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60: 1326-31.
17. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000; 6: 2513-20.
18. Singh B, Cook KR, Vincent L, Hall CS, Martin C, Lucci A. Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res 2010; DOI: 10.1016/j.jss.2010.03.003.
19. Sminia P, Kuipers G, Geldof A, Lafleur V, Slotman B. Cox-2 inhibitors act as radiosensitizers in tumor treatment. Biomed Pharmacother 2005; 59: 272-5.
20. Song YC, Kim SH, Juhnn YS, Song YS. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells. Ann N Y Acad Sci 2007; 1095: 26-34.
21. Chang H, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human colengiocarcinoma growth: Evedence for cyclooxygenase-2-independent mechanism in celecoxib-mediated Induction of p21 and p27 and cell cycle arrest. Cancer Res 2004; 64: 1369 76.
22. Suo-Lin F, Yun-Lin W, Young-Ping Z, Min-Min Q, Chen Y. Anticancer effects of Cox-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroentorol 2004; 10: 1971-4.
23. Casado M, Molla B, Roy R, et al. Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes. Hepatology 2007; 45: 631-8.
24. Patsos HA, Greenhough A, Hicks DJ, et al. The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Int J Oncol 2010; 37: 187-93.
25. Lanza-Jacoby S, Dicker AP, Miller S, et al. Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther 2004; 3: 417-24.
26. Hasegawa K, Ohashi Y, Ishikawa K, et al. Expression of cyclooxygenase-2 in uterine endometrial cancer and antitumor effects of a selective COX-2 inhibitor. Int J Oncol 2005; 26: 1419-28.
27. Dong M, Johnson M, Rezaie A, et al. Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res 2005; 11: 2265-71.
28. Vecchio AJ, Simmons DM, Malkowski MG. The structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010; 285: 22152-63.
29. Praveen Rao PN, Knaus EE. Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. J Pharm Pharm Sci 2008; 11: 81-110.
30. Hawkey C J. Cox-2 inhibitors. Lancet 1999; 353: 307-14.
31. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 1999-2007.
32. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (Cox) inhibitors for growth inhibition of Cox-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002; 625: 2029-33.
33. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 155: 2742-4.
34. Shureiki D, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates non-steroidal anti-inflamatory drug induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000; 60: 6846-50.
35. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase-G acticvation and attenuated B-catenin. Cancer Res 2000; 60: 6846-50.
36. Lim H, Gupta RA, Ma WG, et al. Cyclooxigenase-2 derived prostaglandin mediates embryo implantation in the mouse via PPAR-delta. Genes Dev 1999; 13: 1561-74.
37. Konstantinopoulos PA, Vandoros GP, Sotiropoulou-Bonikou G, Kominea A, Papavassiliou AG. NF-kB/PPAR-gamma and/or AP-1/PPAR-gamma 'on/off'switches and induction of CBP in colon adenocarcinomas: correlation with Cox-2 expression. Int J Colorectal Dis 2007; 22: 57-68.
38. Elstne E, Muller C, Koshizuka K, et al. Ligands for peroxisomeproliferator-activated receptor inhibits growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Nat Acad Sci 1998; 95: 8806-11.
39. He TC, Chan TA, Vogelstein B, Kinzler KW. PPAR is an APC regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-40.
40. Mineo TC, Ambrogi V, Cufari ME, Pompeo E. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? Eur J Cardiothorac Surg. 2010; 38: 245-52.
41. Yim HW, Jong SH, Kim TY, et al. Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res 2005; 65: 1952-60.
42. Ishikawa TO, Jain N, Herschman HR. Feedback regulation of cyclooxygenase-2 transcription ex vivo and in vivo. Biochem Biophys Res Commun 2009; 378: 534-8.
43. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal regulated kinase/c-jun N-terminal kinase and p38 mitogen-activated potein kinase pathways. J Biol Chem 1998; 273: 32943-49.
44. Liu YW, Wang SA, Hsu TY, Chen TA, Chang WC, Hung JJ. Inhibition of LPS-induced C/EBPdelta by Trichostatin a has a positive effect on LPS-induced Cyclooxygenase 2 expression in RAW264.7 cells. J Cell Biochem 2010; 110(6): 1430-8.
45. Wang Y, Yin B, Liu S, Xue S. Cardioprotective effect by tumor necrosis factor-alpha and interleukin-6 through late preconditioning in unstable angina patients. Arch Med Res 2007; 38: 80-5.
46. Ke J, Long X, Liu Y, et al. Role of NF-kappaB in TNF-alphainduced COX-2 expression in synovial fibroblasts from human TMJ. J Dent Res 2007; 86: 363-7.
47. Hsieh HL, Wu CB, Sun CC, Liao CH, Lau YT, Yang CM. Sphingosine-1 phosphate induces Cox-2 expression via P13K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells. J Cell Physiol 2006; 207: 757-66.
48. Båge T, Lindberg J, Lundeberg J, Modéer T, Yucel-Lindberg T. Signal pathways JNK and NF-kappaB, identified by global gene expression profiling, are involved in regulation of TNFalphainduced mPGES-1 and COX-2 expression in gingival fibroblasts. BMC Genomics. 2010; 11: 241, DOI: 10.1186/1471-2164-11-241.
49. Chen P, Cai Y, Yang ZG, et al. Involvement of PKC, p38, MAPK and AP-2 in IL-B-induced expression of cycloxygenase-2 in human pulmonary epithelial cells. Respirology 2006; 11: 18-23.
50. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandinendoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995; 270: 24965-71.
51. Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem 2000; 275: 6259-66.
52. Weilin Xie, Harvey R. Herschman. V-src Induces Prostaglandin Synthase 2 Gene Expression by Activation of the c-Jun N-terminal Kinase and the c-Jun Transcription Factor. J Biol Chem 1995; 270: 27622-8.
53. Jing Chen, Min Zhao, Reena Rao, Hiroyasu Inoue, Chuan-Ming Hao. C/EBP and Its Binding Element Are Required for NFkBinduced Cox-2 Expression Following Hypertonic Stress. J Biol Chem 2005; 280: 16354-9.
54. Han JA, Kim J, Ongusaha PP, et al. p53 mediated induction of Cox-2 counteracts p53-or genotoxic stress-induced apoptosis. The EMBO J 2002; 21: 5635-44.
55. Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cycloxygenase-2. J Biol Chem 2006; 281: 12210-7.
56. Flockhart RJ, Diffey BL, Farr PM, Lloyd J, Reynolds NJ. NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure. FASEB J 2008; 22: 4218-27.
57. Cow LW, Zhu L, Loo WT, Lui EL. Aberrant methylation of cycloxygenase-2 in breast cancer patients. Biomed Pharmacother 2005; 59: 264-7.
58. Nie D. Cyclooxygenases and lipoxygenases in prostate and breast cancers. Front Biosci 2007; 12: 1574-85.
59. Ferguson HR, Wild CP, Anderson LA, et al. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 727-31.
60. Lee JM, Mao JT, Krysan K, Dubinett SM. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol 2007; 3: 149-53.
61. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol 2009; 62: 690-3.
62. Koki AT, Leahy KM, Masferrer JL. Potential utility of Cox-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investing Drugs 1999; 8: 1623-38.
63. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003; 37: 179-92.
64. Masferrer JL, Leahy KM, Koki AT, et al. Anti-angiogeneic and anti-tumor activities of Cyclooxigenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.
65. Wu XZ. New strategy of antiangiogenic therapy for hepatocellular carcinoma. Neoplasma. 2008; 55: 472-81.
66. Sakamoto J, Origuchi T, Okita M, et al. Immobilization-induced cartilage degeneration mediated through expression of hypoxiainducible factor-1alpha, vascular endothelial growth factor, and chondromodulin-I. Connect Tissue Res 2009; 50: 37-45.
67. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell 1995; 83: 493-501.
68. Tian H, McKnight S L, Russel DW. Endothelial pass domain protein I (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
69. Yuan B, Ohyama K, Bassho T, Toyoda H. Contribution of inducible nitric oxide synthase and cyclooxygenase-2 to apoptosis induction in smooth chorion trophoblast cells of human fetal membrane tissues. Biochem Biophys Res Commun 2006; 341: 822-7.
70. Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimäki A, Haglund C. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 2010; 31: 1-7.
71. Liu CH, Chang SH. Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumoregenesis in transgenic mice. J Biol Chem 2001; 276: 18563-9.
72. Chang LW, Chang YC, Ho CC, Tsai MH, Lin P. Increase of carcinogenic risk via enhancement of cyclooxygenase-2 expression and hydroxyestradiol accumulation in human lung cells as a result of interaction between BaP and 17-beta estradiol. Carcinogenesis 2007; 28: 1606-12.
73. Chen T, Hwang H, Rose ME, Nines RG, Stoner GD. Chemopreventive properties of black raspberries in NNitrosomehylbenzylamine-induced rat esophageal tumoregenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase and c-Jun. Cancer Res 2006; 66: 2853-9.
74. Frasor J, Weaver AE, Pradhan M, Mehta K. Synergistic upregulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines. Endocrinology 2008; 149: 6272-9.
75. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and anti-neoplastic actions of non-steroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase null embryo fibroblasts. J Exp Med 1999; 190: 451-9.
76. Sheng H, Sao J, Basington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276: 18075-81.
77. Antonakopoulos N, Karamanolis DG. The role of NSAIDs in colon cancer prevention. Hepatogastroenterology 2007; 54: 1694-700.
78. Huang M, Sharma S, Mao JT, Dubinett SM. Non small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996; 157: 5512-20.
79. Stolina M, Sharma S, Zhu L, Dubinett SM. Lung cancer cyclooxygenase-2 dependent inhibition of dendritic cell maturation and function. Proc Am Assoc Cancer Res 2000; 41: 6-19.
80. Hwang D, Scollard D, Byrne J, Levin E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-60.
81. Gasparini G, Longo R, Sarmiento RA, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003; 4: 605-15.
82. Brueggemeier RW, Quinn AL, Parret ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140: 27-35.
83. Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier RW. Genetic induction and up regulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med Hypotheses 1999; 52: 291-2.
84. Brueggemeier RW, Diaz-Cruz ES. Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches. Minerva Endocrinol 2006; 31: 13-26.
85. Weise FW, Thompson PA, Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001; 21: 5-10.
86. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005; 280: 24053-63.
87. Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol 2007; 30: 785-92.
88. Tinahones F, Salas J, Mayas MD, et al. VEGF gene expression in adult human thymus fat: a correlative study with hypoxic induced factor and cyclooxygenase-2. PLoS One 2009: 14; 4: e8213.
89. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibits alpha-V-beta-3 integrin-mediated and cdc42/Rac-dependent endothelialcell spreading, migration and angiogenesis. Nature Med 2001; 7: 1041-7.
90. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 35451-7.
91. Hsu AL, Ching TT, Wang D-S, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397-403.
92. Zhang L, Tu J, Yu ZL, Wu YD, Xu CM, Zhang ST. Effects of the inhibition of cyclooxygenase-2 on human esophageal cancer cells: inhibition of cell proliferation and induction of apoptosis. Pathol Oncol Res 2010; 16: 39-45.
93. Iwase M, Takaoka S, Uchida M, et al. Accelerative effect of a selective cycloxygenase-2 inhibitor on Fas-mediated apoptosis in human neutrophils. Int Immunopharmacol 2006; 6: 334-41.
94. Alam M, Wang JH, Coffey JC, et al. Characterization of the effects of Cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines. Ann Surg Oncol 2007; 30: 2678-84.
95. Li M, Wu X, Xu XC. Induction of apoptosis in colon cancer cells by cyclooxigenase-2 inhibitor NS398 through a Cytochrome-cdependent pathway. Clin Cancer Res 2001; 7: 1010-16.
96. Nzeako UC, Guicciardi ME, Yoon J-H, Bronk SF, Gores GF. Cox-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002; 35: 552-9.
97. Krysan K, Merchant FH, Zhu L, et al. Cox-2-dependent stabilization of survivin in non-small cell lung cancer. The FASEB J 2003; 18: 206-8.
98. Khan Z, Tiwari RP, Mulherkar R, et al. Detection of survivin and p53 in human oral cancer: correlation with clinicopathological findings. Head and Neck 2009; 31: 1039-48.
99. Khan Z, Bhadouria P, Radha Gupta, Bisen PS. Tumor control by manipulation of the human anti-apoptotic survivin gene. Curr Cancer Ther Rev 2006; 2: 73-9.
100. Khan Z, Khan N, Varma AK, et al. Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel. Curr Cancer Drug Targets 2010; 10: 660-9.
101. Khan Z, Khan N, Tiwari RP, Patro IK, Prasad GBKS, Bisen PS. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 2010; 96: 267-73.
102. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to Cox-2 expression and DCIS recurrence. Br J Cancer 2006; 94: 253-8.
103. Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-3.
104. Tang X, Sun YJ, Half E, Kou MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression confers resistance to tumor necrosis factor-related apoptosis-inducing ligand induced apoptosis in human colon cancer cell. Cancer Res 2002; 62: 4903-8.
105. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A. Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274: 10911-5.
106. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc 716 mice by inhibition of cyclooxygenase-2 (Cox-2). Cell 1996; 87: 803-9.
107. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
108. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-3.
109. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncology Reports 2000; 7: 1377-81.
110. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277: 18649-57.
111. Benoit V, Relic B, de Leval X, Chariot A, Merville M-P, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 2004; 23: 1631-35.
112. Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, Zennami K, et al. Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol Rep 2010; 23: 1577-83.
113. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (Cox-2) inhibitors. BMC Cancer 2006; 6: 27-32.
114. Sooriakumaran P, Langley SE, Laing RW, Coley HM. COX-2 inhibition: a possible role in the management of prostate cancer? J Chemother 2007; 19: 21-32.
115. Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, et al. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 2010; 9: 1371-7.
116. Rijcken FE, Hollema H, van der Zee AG, van der Sluis T, Boersma-van Ek W, Kleibeuker JH. Sulindac treatment in hereditary non-polyposis colorectal cancer. Eur J Cancer 2007; 43: 1251-6.
117. Hawk E, Viner JL. The Adenoma Prevention with Celecoxib and Prevention of Colorectal Sporadic Adenomatous Polyps Trials: Stepping Stones to Progress. Cancer Epidemiol Biomarkers Prev 2007; 16: 185-7.
118. Singh B, Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res 2002; 108: 173-9.
119. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Onco1 2004; 31: 64-73.
120. Gabriel N, Hortobagyi. Trastuzumab in the Treatment of Breast Cancer. N Engl J Med 2005; 353: 1734-6.
121. Ershler WB. Capecitabine Monotherapy: Safe and Effective Treatment for Metastatic Breast Cancer. The Oncologist 2006; 11: 325-35.
122. Chow LWC, Toi M. Prospective pilot study of the preoperative use of celecoxib (Celebrex (TM) and FEC for the treatment of locally advanced breast cancer. Breast Cancer Res Treat 2002; 76: 154-67.
123. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, et al. Clifford A. Hudis. Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments. Clin Cancer Res; 2004; 10: 4062-7.
124. Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, et al. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 2008; 62: 717-25.
125. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996; 137: 5739-42.
126. Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 2001; 79: 103-7.
127. Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 2003; 86: 443-7.
128. Maaser K, Däubler P, Barthel B, Heine B, von Lampe B, Stein H, et al. Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br J Cancer 2003; 88: 1217-22.
129. Kim K, Wu HG, Park SW, Kim CJ, Park C. Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer. Cancer Res Treat 2004; 36: 187-91.
130. Kim YY, Lee EJ, Kim YK, Kim SM, Park JY, Myoung H, et al. Anti-cancer effects of celecoxib in head and neck carcinoma. Mol Cells 2010; 29: 185-94.
131. Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, et al. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 2007; 26: 1920-31.
132. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M. Cyclooxygenase-2 (COX-2) mRNA Expression Levels in Normal Lung Tissues and Non-small Cell Lung Cancers. Jpn J Cancer Res 1999; 90: 1338-43.
133. Mascaux C, Martin B, Verdebout JM, Ninane V, Sculier JP. COX-2 expression during early lung squamous cell carcinoma oncogenesis. Eur Respir J 2005; 26: 198-203.
134. Qadri SS, Wang JH, Redmond KC, O' Donnell AF, Aherne T, Redmond HP. The role of COX-2 inhibitors in lung cancer. Ann Thorac Surg 2002; 74: 1648-52.
135. Park SY, Kim YM, Pyo H. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated Molecular Cancer 2010, 9: 222, DOI: 10.1186/1476-4598-9-222.
136. Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer. Semin Oncol 2004; 31: 45-52.
137. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, et al. A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non-Small Cell Lung Cancer. Clin Cancer Res 2005; 11; 3342-8.
138. Chen L, He Y, Huang H, Liao H, Wei W. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on nonsmall cell lung cancer cell lines: in vitro toxicity and mechanism study. Med Oncol 2008; 25, 161-71.
139. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86: 667-71.
140. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 Is Overexpressed in Human Cervical Cancer. Clin Cancer Res 2001; 7: 429-34.
141. Wülfing C, Eltze E, von Struensee D, Wülfing P, Hertle L, Piechota H. Cyclooxygenase-2 Expression in Bladder Cancer: Correlation with Poor Outcome after Chemotherapy. Eur Urol 2004; 45, 46-52.
142. Michalowski J. COX-2 Inhibitors: Cancer Trials Test New Uses for Pain Drug. J Natl Cancer Inst 2002; 94: 248-49.
143. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention for the Adenoma Prevention with Celecoxib (APC) Study Investigators. N Engl J Med 2005; 352: 1071-80.